What do the new evolutions in GI cancer mean for my practices
|
|
- Jesse Chase
- 5 years ago
- Views:
Transcription
1 What do the new evolutions in GI cancer mean for my practices South (and Latin) America view Jorge Gallardo MD Medical Oncologist Santiago de Chile. «SLAGO working group» Chilean Foundation for Development Oncology 1
2 What do the new evolutions in GI cancer mean for my practices 1. Economic and social backgrounds 2. New drugs in metastatic disease 3. Adjuvant protocols 4. Radiotherapy 5. Diagnostic tests 6. Clinical Trials 7. New Guidelines 2
3 Economic and social backgrounds South America has 416, Latin America has 623 million people, (10% of world population) Gastric Cancer Colorectal cancer The cancer epidemiology in Latin America differs from that found in other regions:* higher incidence in gastric cancer Highest gallbladder cancers mortality mainly in Andean Pacific area Uruguay and Argentina have the highest incidence and mortality rate in colon, rectal and pancreatic cancers in the world**, East Atlantic area Galblader Cancer Esophageal Cancer Brazil and Uruguay the highest mortality rate in esophageal cancer** Ref: *Torre et al. 2015; ** Globocan 2012, Estimated incidence, mortality worldwide 3
4 2016 Portugal 30.2 Greece 26.7 Turkey 25.2 Poland 27.4 Latin America comprise low and mid per capita income countries in a great heterogeneous scenario 4
5 Investment in health according to OECD and WHO 5
6 With almost a fifth of expenditure per capita life expectancy is higher in Chile compared to USA Health expenditure per capita Life expectancy OECD 9.0% ($4 000) Life expectancy at birth (years) Life expectancy at age 60 (years) Both male female Both male female sexes sexes USA Chile Canada Uruguay Chart breaks it down by public and private expenditure In year 2012, Statistic 2014, last available static, accessed Feb/2017 Ref: Health expenditure per capita, 2014 (OECD stat); World health statitics, WHO
7 Health insurance systems in Chile and South America Public system 80% of overall population, including The poorest people Oldest (retired) Less educated Some handicaped and chronically ill patients Solidarity Equal access to health Saturated Old technology Each test done, every patient treated, means spending money Private system 15 % of population The richest part Active part (working actively) Best educated, high level Must be healthy when entering Insurance system Individualist Access to health according to «insurance primeum» Open to receiving patients New technology Each test done, every patient treated, means earning money Medicine Free Market Economic and social inequity is a generalized characteristic 7
8 What do the new evolutions in GI cancer mean for my practices 1.- A new expensive drug : i.e. Immunotherapy Public system It will take a lot of time to be included Some will never be included. When included, all population will have access to it To include a new expensive drug Increases expenditure Private system Almost all of them will be included They are already being used Oncologists are trying to get knowledge and training how to use it Price is less important/unimportant Access depends on quality of insurance It may increase Pats financial distress To include new expensive drugs Gives prestige Increases financial income to the private clinic
9 2.- Advances in neo or adjuvant therapies Adjuvant therapies utilize, commonly, old and/or cheaper drugs MAGIC and FLOT; FOLFOX and CAPOX, Gemcit adjuvant, etc. were rapidly included Neoadjuvant chemo-radiation for rectal cancer was rapidly introduced Chemo-radiation for esophageal cancer has been standard for a long time, nowadays with CROSS GOOD IMPACT!!! 9
10 3.- New technology for diagnosis: New MRI, CT, PET-CT Public system It takes time to get the machines Old technology Deficits, i.e. Only one PET-CT available for 80% of population Deficits in radiologists Pts get appointment with long delays To obtain report takes additional long time Saturated Each test done means spending money Private system All has been rapidly incorporated Less deficit, i.e. 6 PET-CT available for 20% of population No deficits on radiologists Access depends on quality of insurance Appointments for tests are obtained rapidly, reports are given faster Report and images are available through internet for Pats Open to receive patients Each test done means earning money Including new tests gives prestige to the private clinic 10
11 3.- New Technology in Radiotherapy Ref: Expanding Global Access to Rtx, Lancet Oncology Commission 11
12 3.- New Technology in Radiotherapy Public system Private system It takes time to have the new machines Deficits in specialists Pts get therapy with long delays Oversaturated Old technology All has been rapidly incorporated No deficits on radiotherapists Access depends on quality of insurance Appointments for treatment are obtained rapidly Open to receive patients Ref: Expanding Global Access to Rtx, Lancet Oncology Commission 12
13 4.- Advances in new molecular tests New molecular tests are related to new expensive drugs Frequently, tests are offered for free by the pharmaceutical companies Most tests are available in main cities of South- America Laboratories for DNA sequencing and other tests performed under fast delivering logistics are limited to few academic and private institutions. 13
14 5.- Participation in clinical trials The largest average annual growth in clinical trial participation occurred in lower-middle and low-income regions: Asian 30% Latin American countries 12%. Three Latin American countries ranked among the top 25 countries with high participation in pharmaceutical clinical trials: Argentine, Brazil and Mexico In terms of technology, research sites vary considerably Eccard et al. 2016; Thiers, Sinskey, and Berndt
15 5.- Participation in international clinical trials Many Latin American researchers are taking part in nowadays running trials Some researchers get to be one of top enrollers Until now, participation doesn t include the study design We are increasingly reluctant to publications/studies that don t include Latin American population Growth of clinical research infrastructure acts as a driver of overall health system development by introducing strong organizational and regulatory mechanisms and building local capacity and expertise in the medical field Lastly, increasing access to clinical trials in LMICs allow patients access to medicines that might be, otherwise, inaccessible 15
16 6.- IMPACT OF NEW GUIDELINES NCCN and ESMO guidelines are well known, but the updates are much less known In English Accessible only by internet Few accesses are available in crowded public hospitals Affordability of drugs/regimens are different Small impact, if any, in daily practice No impact in governmental decisions Reference for some insurance companies To have ESMO guidelines adapted to Latin America can impact the quality of cancer care!! 16
17 Five years Survival in Gastrointestinal Cancers in South America, Quinquenium (Reference two European countries) Oesophagus Stomach colon rectum liver pancreas Germany Spain , Argentine Brazil Chile Colombia Ecuador Uruguay y Survival 5 years survival colon cancer Quinqueniun Quinq Adapted from Concord Study The lancet March 2018
18 What do the new evolutions in GI cancer mean for my practices 1. Due to economic and social background there are big differences, high inequity 2. Less than 5-15% can have access to new expensive drugs in LA 3. New protocols using old drugs are rapidly included, specially in adjuvant setting 4. Radiotherapy, radiology, new diagnostic tests: available in big cities, mostly for a minority 5. Clinical Trials: Have accelerated increment, good impact 6. New Guidelines: Little impact in normal practices 7. In GI cancers the 5 years survival is much inferior to Europe and did not improve in last quinquenium New advances are associated with financial toxicities If we know the advances in oncology we can improve the results in prevention, quality of life, life expectancy, cure rate. 18
19 19
20
Academic Research in LA
Academic Research in LA Dr. Carlos H. Barrios Faculdade de Medicina, PUCRS Instituto do Câncer, HMD LACOG, Latin American Cooperative Oncology Group Porto Alegre, Brasil 36% improvement Age-Adjusted Male
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationTrends and disparities in cancer in Aotearoa/ NZ
Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both
More informationCurrent Status in Latin America
WHO International Consultation 15 to 17 October 2014 Munich, Germany JUSTIFICATION OF THE USE OF CT FOR INDIVIDUAL HEALTH ASSESSMENT OF ASYMPTOMATIC PEOPLE Current Status in Latin America Gloria Soto Giordani
More informationTHE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER
THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER INTERNATIONAL HEALTH International health has been seen as
More informationCANCER CONTROL IN CHILE AN UNDERFUNDED SYSTEM WITH POCKETS OF STRENGTH
HIGHLIGHTS The Economist Intelligence Unit has created a unique scorecard, the Latin America Cancer Control Scorecard (LACCS), which covers policies and programmes designed to reduce inequality in cancer-care
More informationColorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial
Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial ANNUAL REPOR T (562) 933-0900 MemorialCare.org/TCI 2810 Long Beach Blvd. Long Beach, CA 90806 #3 Colorectal cancer is
More informationCYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.
CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5
More informationTraining a new generation of radiation oncologists in Latin America Celine K. Torzsok
Training a new generation of radiation oncologists in Latin America Celine K. Torzsok FALP Santiago de Chile Why a Master in Advanced Radiation Therapy? Quick advances in technological skills and knowledge:
More informationThe reality of cancer clinical trials in Latin America
The reality of cancer clinical trials in Latin America Gustavo Werutsky Latin American Cooperative Oncology Group (LACOG) 18 April 2018, Mexico City, Mexico None Conflicts of Interest Cancer in Latin America
More informationGlobal Radiation Therapy Market Report
Global Radiation Therapy Market Report ----------------------------------------- 2013 Executive Summary Radiotherapy is used to kill cancerous cells and is commonly used either alone or in combination
More informationBuilding a strategy for 2025: uniting evidence and policy to achieve cancer control for all
Building a strategy for 2025: uniting evidence and policy to achieve cancer control for all Building on commissions: Latin America in 2015 Diego Touya, MD Number (code): 4-T2 Track 2 Disclosure of interest:
More informationMeeting the MDGs in South East Asia: Lessons. Framework
Meeting the MDGs in South East Asia: Lessons and Challenges from the MDG Acceleration Framework Biplove Choudhary Programme Specialist UNDP Asia Pacific Regional Centre 21 23 23 November 2012 UNCC, Bangkok,
More informationFEASIBILITY ASSESSMENT: CORNERSTONE OF SUCCESSFUL CLINICAL TRIAL PLANNING
FEASIBILITY ASSESSMENT: CORNERSTONE OF SUCCESSFUL CLINICAL TRIAL PLANNING VERONIKA FEKETE, MD MANAGER FEASIBILITY RESEARCH AND PATIENT RECRUITMENT SERVICES, PSI CRO 1 WHAT CAN GO WRONG WITH A CLINICAL
More informationSirtex Medical Limited (ASX:SRX)
Sirtex Medical Limited (ASX:SRX) Macquarie Australia Conference Mr Gilman Wong, CEO Dr David Cade, CMO Sydney, 8 th May 2014 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1 Understanding
More informationTobacco & Poverty. Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That. Introduction. Impacts of Tobacco Use on the Poor
Policy Brief February 2018 Tobacco & Poverty Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That Introduction Tobacco use is the world s leading cause of preventable diseases and premature
More informationo Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017
o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH-10401 Publishing Date: July, 2017 Sr. No. License Type Price 1 Single User License $4,175.00 2 Multiple User
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationBrazil: The Gem of Latin America. October 2011
Brazil: The Gem of Latin America October 2011 The Importance of Latin America to Pharma The Latin American pharmaceutical market is among the fastest growing in the world and is expected to be $51.3 billion
More information7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift
People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and
More informationAsia s Diabetes Challenge
Asia s Diabetes Challenge 12 th Geneva Association Health and Aging Conference Karl-Heinz Jung Head, Japan, MENA & International 1. Facts about Diabetes 2. Asia Feeling the Heat 3. Case for Private Insurance
More informationReferences to Uruguay
References to Uruguay Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES The global picture Regional trends in illicit drug use South
More informationStrategic Business Overview. Bernard HOURS
Strategic Business Overview Bernard HOURS 2000-2007: Continuous growth 8% Volume 10% Sales 14% EBIT 7% 6% 5% 4% 3% 2% 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% 12% 10% 8% 6% 4% 2% 0% 0% 0% 2000 2007 2000 2007 2000
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More information7/11/2011. The impact of cancer survival studies on health policy. NCI prevention budget falls. Cases Deaths Survivors
The impact of cancer survival studies on health policy North American Association of Central Cancer Registries Louisville KY, 21 June 2011 NCI prevention budget falls Cancer burden set to rise Cases Deaths
More informationOncology in Emerging Markets
Oncology in Emerging Markets W H I T E P A P E R Toll Free : (888) 987-2691 www.makrocare.com/mcsmo 1 www.makrocare.com/mcsmo C W H I T E P A P E R ancer has been the leading cause of death in economically
More informationSession V: The Programme of Action for Cancer Therapy - PACT
Session V: The Programme of Action for Cancer Therapy - PACT Ms Nelly Enwerem-Bromson Director Division of Programme of Action for Cancer Therapy Department of Technical Cooperation International Atomic
More informationAnalysis of access to innovative medicines in Chile compared to other OECD countries
Analysis of access to innovative medicines in Chile compared to other OECD countries Comparative indicators on access to new molecular entities in Chile November 2018 Commisioned by: 1 2 This analysis
More informationPart 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES
References to Brazil Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES The global picture Cocaine In 2010, the regions with a high
More informationReferences to Argentina Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS
References to Argentina Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES The global picture Cocaine In 2010, the regions with a
More information650, Our Failure to Deliver
650, Our Failure to Deliver, Director UAB Comprehensive Cancer Center Professor of Gynecologic Oncology Evalina B. Spencer Chair in Oncology President, American Cancer Society All Sites Mortality Rates
More informationBreast Cancer in the Eastern Mediterranean Region A Burden with Potential. King Hussein Cancer Center
Breast Cancer in the Eastern Mediterranean Region A Burden with Potential Presented by: Mahmoud M. Sarhan, MD, MMM, CPE CEO & Director General Presented at: International Symposium on Breast Cancer in
More informationMEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS IAS040B October 2016 Paul Taylor Project Analyst ISBN: 1-62296-372-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationComplexity of the Global Approach to Control Obesity: Challenges for implementation in Mexico
Roundtable on Obesity Solutions National Academies of Sciences, Engineering, and Medicine Complexity of the Global Approach to Control Obesity: Challenges for implementation in Mexico Dr. Simón Barquera,
More informationEpidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers Dr Ian Chau Consultant Medical Oncologist Women's cancers Breast cancer introduction 3 What profession are you in?
More informationWe are seeking to supply governments and private parties with affordable versions of drugs to treat HCV.
March 18, 2015 Mr. Gregg Alton Executive Vice President, Corporate and Medical Affairs Gilead Sciences 333 Lakeside Drive Foster City, CA 94404 Via Email: gregg.alton@gilead.com Re: Request for license
More informationColorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
More informationProspective Urban Rural Epidemiologic ( PURE) Study.
Prospective Urban Rural Epidemiologic ( PURE) Study. 17 HIC, MIC and LIC countries, 628 urban and rural communities, 154,000 randomly selected, BP measured using an Omron with standard methods in 90%.
More informationClosing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011
Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and
More informationPRECEPTORSHIP PROGRAMME
esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland
More informationCombined FOXFIRE Study Data Presented at ASCO Annual Meeting
ASX/MEDIA RELEASE 6 th June 2017 Combined FOXFIRE Study Data Presented at ASCO Annual Meeting Sydney, Australia; 6 th June 2017 Sirtex Medical Limited (ASX:SRX) announces the oral abstract of the combined
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationPerspectives on national decision makers: The healthcare policy maker
Perspectives on national decision makers: The healthcare policy maker Osnat Luxenburg Director of Medical Technology Administration Ministry of Health, Israel Health Policy Constructing national policy
More informationEPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets
EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns
More informationOncology Clinical Trials in Emerging Regions A Trend Analysis
Oncology Clinical Trials in Emerging Regions A Trend Analysis W H I T E P A P E R Toll Free Number: 1-888-987-2691 1 Cancer represents considerable unmet medical need and has been leading cause of death
More informationDelivering Affordable Cancer Care death of a dream?
Delivering Affordable Cancer Care death of a dream? Richard Sullivan MD PhD Prof, Cancer Policy & Global Health academia.edu/richardsullivan Affordability & sustainability are complex & multifaceted public
More informationATRIAL FIBRILLATION AROUND THE WORLD/ CONTINENTAL PERSPECTIVES AND SPECIFICITIES: SOUTH AMERICA. LUIS AGUINAGA MD, PhD, FESC,FACC Argentina
ATRIAL FIBRILLATION AROUND THE WORLD/ CONTINENTAL PERSPECTIVES AND SPECIFICITIES: SOUTH AMERICA LUIS AGUINAGA MD, PhD, FESC,FACC Argentina 2010 Global Burden of Disease Study Chugh, S. S. et al. Circulation,
More informationProf. Dr. med. Hans-Joachim Schmoll Biography
Prof. Dr. med. Hans-Joachim Schmoll Biography PubMed N publications: 445 Cumulative Impact factor: 1697 Web of Science Citation factor (h; Hirsch): 71 N Citations/year: 2017 1645 Short-CV Since 4 decades,
More informationEconomics of Tobacco in Argentina
Economics of Tobacco in Argentina Consumption and Prevalence?? In 1999, Argentina was the third largest cigarette consumption country in the Latin America & Caribbean region (LAC), accounted for 15% of
More informationCancer incidence, mortality and survival for health policy and cancer control
Cancer incidence, mortality and survival for health policy and cancer control Cáncer 2019: Impacto Social y Económico y Alianzas Público-Privadas Universidad Católica de Chile 23 de agosto de 2018 World
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationFor personal use only
AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More information39th SESSION OF THE SUBCOMMITTEE ON PLANNING AND PROGRAMMING OF THE EXECUTIVE COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 39th SESSION OF THE SUBCOMMITTEE ON PLANNING AND PROGRAMMING OF THE EXECUTIVE COMMITTEE Washington, D.C., USA, 16-18 March 2005 Provisional Agenda
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationThe New Danone : A unique food company. Autumn Conference 2008 CA Cheuvreux
The New Danone : A unique food company Autumn Conference 2008 CA Cheuvreux September 26th, 2008 Disclaimer This document contains certain forward-looking statements concerning Groupe DANONE. Although Groupe
More informationENDING AIDS, TB AND MALARIA AS EPIDEMICS
ENDING AIDS, TB AND MALARIA AS EPIDEMICS A SMART INVESTMENT In 2000, AIDS, tuberculosis and malaria appeared to be unstoppable. In many countries, AIDS devastated an entire generation, leaving countless
More informationENDING AIDS, TB AND MALARIA AS EPIDEMICS
ENDING AIDS, TB AND MALARIA AS EPIDEMICS A SMART INVESTMENT In 2000, AIDS, tuberculosis and malaria appeared to be unstoppable. In many countries, AIDS devastated an entire generation, leaving countless
More informationThe Cigarette Market in Greece
The Cigarette Market in Greece Product Code: CG0145MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Greece report is a qualitative report providing extensive and
More informationTHE COST DRIVERS OF CANCER CARE
THE COST DRIVERS OF CANCER CARE Debra Patt, MD, MPH, MBA David Eagle, MD Ted Okon, MBA Don Sharpe 20156Community Oncology Alliance 1 Welcome & Introductions Debra Patt, MD, MPH, MBA Director of Public
More informationPatients With Colorectal Cancer: Guidebook (Korean Edition) READ ONLINE
Patients With Colorectal Cancer: Guidebook (Korean Edition) READ ONLINE If searching for the book Patients with colorectal cancer: Guidebook (Korean edition) in pdf format, in that case you come on to
More informationEconomic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US
Economic Implications of Advancements in Radiation Technology Sponsored by: OTN Anthony M. Berson, M.D. Radiation Oncology, St. Vincent s Comprehensive Cancer Center Richard Emery Vice President, Aptium
More informationReflecting on ten years of progress in the fight against AIDS, TB and malaria
Reflecting on ten years of progress in the fight against AIDS, TB and malaria Michel Kazatchkine UN Secretary General s Special Envoy on HIV/AIDS in Eastern Europe and central Asia Ten years of progress:
More informationKelly D. Post RN, BSN, OCN Gastrointestinal Nurse Navigator Advocate Christ Medical Center, Cancer Institute April 5, 2014
Kelly D. Post RN, BSN, OCN Gastrointestinal Nurse Navigator Advocate Christ Medical Center, Cancer Institute April 5, 2014 Objectives Explain responsibilities of Gastrointestinal (GI) Nurse Navigator Review
More informationPopulation- based cancer survival estimates
Population- based cancer survival estimates Represent average prognosis of cancer in a specific population Socio-economic features Health care seeking behaviours Coverage and quality of health care services
More informationLarge observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)
Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE) John Laffey, Giacomo Bellani, Tai Pham, Eddy Fan, Antonio Pesenti on behalf of the LUNG SAFE Investigators
More informationGlobal Strategies to Improve Cancer Care and Control
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Global Strategies to Improve Cancer Care and Control Tbilisi, Georgia October 15-16, 2013 Julie R. Gralow, M.D. Jill Bennett Endowed Professor
More informationProbiotics in Latin America. Regulation, Market and Trends
PROBIOTA 2018 PANEL DEBATE: Regulation and policy: The shifting sands of Europe Barcelona, February 8th, 2018 Probiotics in Latin America. Regulation, Market and Trends Dr Javier Morán Director. IIA-Instituto
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More informationNHS Healthcare Science. Cumbria & NE LWAB. 4 th September 2018
NHS Healthcare Science Cumbria & NE LWAB 4 th September 2018 Executive Summary The Business Proton Partners International (PPI) will build, own and operate a network of Proton Beam Therapy Cancer Centres
More informationWhat Does Breast Cancer Treatment Cost and What Is It Worth?
What Does Breast Cancer Treatment Cost and What Is It Worth? Elena B. Elkin, PhD Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center Is This Drug Worth the Cost? Ixabepilone added
More informationGisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services
Gisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services Challenges to the Health Sector External Context Complexity of health determinants Multiplicity of initiatives
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationGastrointestinal Multidisciplinary Cancer (GI MDC) Navigation May 3, 2012
Gastrointestinal Multidisciplinary Cancer (GI MDC) Navigation May 3, 2012 Coralyn Martinez MSN, RN, OCN GI Nurse Navigator The Lacks Cancer Center Saint Mary s Health Care Grand Rapids, MI History of
More informationPROTON THERAPY. MEDraysintell WORLD MARKET REPORT & DIRECTORY EDITION
MEDraysintell PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2018 A report written by Paul-Emmanuel Goethals & Richard Zimmermann 2018 www.medraysintell.com Proton Therapy remains a niche market,
More informationLa obesidad puede matar: el papel de primaria de la salud y la prevención del cáncer.
La obesidad puede matar: el papel de primaria de la salud y la prevención del cáncer. Obesity can kill: the role of primary health and cancer prevention. Luigi Ricciardiello, MD Department of Medical and
More informationCapacity building for research and management of cancer patients (before), during and after military conflicts
Capacity building for research and management of cancer patients (before), during and after military conflicts Richard Sullivan MD PhD Institute of Cancer Policy Conflict & Health Research Group Reality
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationHOOKVAC EU-US-Africa collaboration towards a vaccine for hookworm
HOOKVAC EU-US-Africa collaboration towards a vaccine for hookworm Remko van Leeuwen GLOBAL HEALTH POLICY FORUM 12 JUNE 2014, 13:00-16:00 AIGHD Remko van Leeuwen The Vaccine Translational Research Gap HOOKVAC
More informationHow Does Adding Vectibix to Colorectal Cancer Care Plans Compare to Supportive Care Alone?
Clinical Study Results 1. Study Name What does this summary cover? This summary shows the main results from one clinical study. The results are only for this study. Other studies may find different results.
More informationHistiocytosis in Argentina Since 1991
Histiocytosis in Argentina Since 1991 AIM To present the experience of a multidisciplinary study group focused on rare and complex histiocytic disorders. Langerhans Cell Histiocytosis (LCH) Disregulation
More informationAn increasing demand for livestock directly translates into increasing demand for animal feed and animal
An increasing demand for livestock directly translates into increasing demand for animal feed and animal feed additives such as vitamins. Synthetic vitamin E is the key ingredient used in global animal
More informationDiabetic Eye Care; Workforce Challenges and opportunities
Diabetic Eye Care; Workforce Challenges and opportunities Hugh R. Taylor, AC, MD April 2013 Bangkok How many ophthalmologists in practice and training worldwide? Study designed and conducted by ICO in
More informationThe Global Summit of Women 2009 Santiago, Chile May 14-16
The Global Summit of Women 2009 Santiago, Chile May 14-16 Presentation on Combating Violence Against Women By Susan Arnot Heaney, Global Director, Corporate Responsibility, Avon Products, Inc. (USA) Public
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationGlobal E-Cigarette & Vaporizer Market Research Report - Forecast to 2027
Report Information More information from: https://www.marketresearchfuture.com/reports/788 Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027 Report / Search Code: MRFR/CR/0304-CRR
More informationAn Overview of Health Economics Data and Expertise in Cancer
An Overview of Health Economics Data and Expertise in Cancer Peter Smith, (Professor of Health Policy, Imperial College London) Mauro Laudicella (Research Fellow, Imperial College London) Source: A. Maynard
More informationReady for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal.
Ready for a CRO That Values Performance Over Promises? CHALLENGE At Clinipace, it s personal. Who We Are At Clinipace, It s Personal. We Will PROVE IT. With us, you get the A team. We deliver a level of
More informationDefeating Colon Cancer with Surgery
Defeating Colon Cancer with Surgery Recorded on: September 19, 2012 Alessandro Fichera, M.D. Director, Colorectal Surgical Oncology Program, Seattle Cancer Care Alliance Please remember the opinions expressed
More informationJohns Hopkins individualized Health Initiative
Johns Hopkins individualized Health Initiative Hopkins inhealth Scott L. Zeger Professor of Biostatistics Vice Provost for Research Chair, Johns Hopkins Individualized Health Steering Committee May 16,
More informationGOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights
GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION (indicator G2.2) Highlights As of December 2014, 140 Member States had introduced rubella vaccines; coverage, however, varies from 12% to 94% depending on region.
More informationPolicies on access and prices
Policies on access and prices Rosa Carolina Sandoval, MPA San Juan, Puerto Rico March 15, 2006 Access policies Youth access laws: designed to limit the availability of tobacco from commercial sources to
More informationJules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President
Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer
More informationWhat are the various Motives for Patients to Travel? -Dr Samit Sekhar Executive Director
What are the various Motives for Patients to Travel? -Dr Samit Sekhar Executive Director Reproductive Tourism Assisted reproductive technology (ART) lures people across borders. The willingness to travel
More informationCONNECTED HEALTH TRENDS
CONNECTED HEALTH TRENDS 2018 A CONNECTED HEALTH MOVING IN THE RIGHT DIRECTION The figure 10,000 is now synonymous with the number of steps we should all be striving for each day to help maintain a healthy
More informationThe Diagonal Approach to Health System Strengthening: A Roadmap for Expanding Access in LMICs August 28th, World Cancer Congress, Montreal
The Diagonal Approach to Health System Strengthening: A Roadmap for Expanding Access in LMICs August 28th, 2012 World Cancer Congress, Montreal Felicia Marie Knaul, PhD Harvard Global Equity Initiative,
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationPROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT
UNITED NATIONS A General Assembly Distr. LIMITED A/HRC/11/L.16 16 June 2009 Original: ENGLISH HUMAN RIGHTS COUNCIL Eleventh session Agenda item 3 PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL,
More information